No Detail Found!

Systemic Immune-in ammation Index is the Best Prognostic Factor in Patients with Advanced Stage Adenocarcinoma of the Lung Treated with Pemetrexed

Author(s)
Irem Bilgetekin Department of Medical Oncology, HSU Dr. Abdurrahman Yurtaslan, Oncology Training and Research Hospital,Ankara,Turkey
Fatma Bugdayci Basal Department of Medical Oncology, HSU Dr. Abdurrahman Yurtaslan, Oncology Training and Research Hospital,Ankara,Turkey
Abstract
Objective: To evaluate the prognostic role of systemic immune-in ammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in patients who received platin-pemetrexed combination therapy and/or maintenance pemetrexed therapy. Study Design: Observational study. Place and Duration of Study: Department of Medical Oncology, HSU Dr. Abdurrahman Yurtaslan Oncology, Training and Research Hospital, Turkey, between January 2010 and March 2020. Methodology: Data of patients with metastatic adenocarcinoma of lung, who underwent platin-pemetrexed combination therapy and/or maintenance pemetrexed therapy retrospectively, were evaluated. Patient characteristics and disease parameters were recorded. Moreover, NLR, PLR, and SII were calculated. Survival analysis with the Kaplan-Meier and Log-rank test was performed. Cox regression analysis was used to determine independent prognostic factors of overall survivall (OS) and progression-free survival (PFS). Results: In the univariate analyses, NLR-low group and SII-low group had signi cantly longer PFS compared to NLR-high and SII-high groups (10 months vs. 8 months, p=0.018, and 13 months vs. 8 months, p<0.001, respectively). The signi cant di erences were seen between SII-low and SII-high groups for OS (24 months vs. 13 months, p=0.001). In multivariate analyses, response to treatment and low-SII were independent prognostic factors for PFS (HR: 0.25, p<0.001, and HR: 0.47, p=0.002, respectively) and OS (HR: 2.09, p=0.001, and HR: 2.05, p=0.001, respectively). Conclusion: SII is the most powerful of the three studied in ammatory indices, which could independently predict overall and progression-free survival.
Publication Details
Page(s) 933-939
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 30, Issue: 9, Year: 2020

Request the full text from PASTIC

Keywords
Neutrophil-to-lymphocyte ratio, Adenocarcinoma, Lung Cancer, Systemic immune-in ammation index, Pemetrexed, Platelet-to-lymphocyte ratio
0

Citations

0

Downloads

85

Views